Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising…

Amount: Not stated
Type: Grant

Key facts

Key facts for Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
Amount	Not stated
Issuer	National Institutes of Health
Who can apply	US companies
Sectors	HealthTech
Deadline	Closes 19 Nov 2026

Unlock application details

See all eligibility criteria, required documents and the official application link. Free account, no card.

Update history

Source: grants.gov ↗

Source checked yesterday

40 days agoagentImported from the official source

Opportunities with the same funding type or region
AI Growth Lab		Closes 27 Sep 2026
BJA FY 2026 Adult Treatment Court Program	up to $2.5M	Closes 30 Oct 2026
BJA FY 2026 Capital Case Litigation Initiative: Improving the Quality of Legal Representation in State Capital Cases	up to $450,000	Closes 29 Oct 2026